Clinicians should consider switching glaucoma medication within the same class

Article

It is essential that clinicians familiarize themselves with the full spectrum of glaucoma medication available, concludes a study published in the March 2009 issue of Current Opinion in Ophthalmology.

It is essential that clinicians familiarize themselves with the full spectrum of glaucoma medication available, concludes a study published in the March 2009 issue of Current Opinion in Ophthalmology.

Simon K. Law, MD of the Jules Stein Eye Institute at the University of California, US conducted a review of currently available medications to discover if treatments in the same class had similar modes of action and potential adverse events, or if switching to certain medications could offer medical, as well as financial, benefits.

Dr Law found that individual patient response may vary significantly, which could result from factors as diverse as medication compliance, adverse events to medication ingredients or drug-receptor interactions.

Because of these varied factors, Dr Law recommended clinicians be fully versed in currently available treatment, to offer each of their patients the most suitable option.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.